Otelixizumab

#	Item
1	PROGRESS REPORT – TYPE 1 DIABETES TRIALNET TrialNet Progress Report Period – [removed]to[removed]This report reviews the progress made by Type 1 Diabetes TrialNet during the period January 1, 2011 to present. The pu Add to Reading List Source URL: www.diabetestrialnet.org Language: English - Date: 2012-02-20 13:11:44 Diabetes mellitus type 1 Diabetes mellitus American Diabetes Association Rituximab C-peptide Latent autoimmune diabetes Otelixizumab Diabetes Endocrine system Medicine
2	Editorial For reprint orders, please contact [removed] EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop? Expert Rev. Clin. Immunol. 9(2), 95–[removed]) Add to Reading List Source URL: www.faustmanlab.org Language: English - Date: 2013-12-11 22:21:47 Immune system Epstein–Barr virus Teplizumab Otelixizumab Tumor necrosis factor-alpha Anti-CD3 monoclonal antibody Immunosuppressive drug Monoclonal antibody therapy Tolerx Monoclonal antibodies Medicine Immunology